Human papillomavirus-16/18 candidate vaccine adjuvanted with AS04 and its impact on the incidence of cervical cancer

Expert Review of Obstetrics and Gynecology

Volumn 2, Issue 3, 2007, Pages 293-303

  Schwarz, Tino F ^a  

^a Stiftung Juliusspital   (Germany)

Author keywords

AS04; cervical cancer; cervical dysplasia; female; human papillomavirus; immunogenicity; vaccine

Indexed keywords

EID: 85008719801     PISSN: 17474108     EISSN: 17474116     Source Type: Journal    
DOI: 10.1586/17474108.2.3.293     Document Type: Article

References (83)

1. zur Hausen H. Human genital cancer: synergism between two virus infections or synergism between a virus infection and initiating events? Lancet 2 (8312), 1370–1372 (1982).
2. zur Hausen H, Gissmann L, Steiner W, Dippold W, Dreger I. Human papilloma viruses and cancer. Bibl. Haematol. 43, 569–571 (1975).
3. IARC. Human papilloma viruses. IARC Monogr. Eval. Carcinog. Risks Hum. 64 (1995).
4. IARC. Handbooks of cancer prevention. IARC 10 (2005).
5. Munoz N, Bosch FX, de Sanjose S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348 (6), 518–527 (2003).
6. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 324 (1), 17–27 (2004).
7. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase 5 (2.0), IARC Press, Lyon, France (2004).
8. Munoz N, Bosch FX, Castellsague X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer 111 (2), 278–285 (2004).
9. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 88 (1), 63–73 (2003).
10. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol. Biomarkers Prev. 14 (5), 1157–1164 (2005).
11. Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366 (9490), 991–998 (2005).
12. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br. J. Cancer 89 (1), 101–105 (2003).
13. Thomas KK, Hughes JP, Kuypers JM et al. Concurrent and sequential acquisition of different genital human papillomavirus types. J. Infect. Dis. 182 (4), 1097–1102 (2000).
14. Rousseau MC, Villa LL, Costa MC, Abrahamowicz M, Rohan TE, Franco E. Occurrence of cervical infection with multiple human papillomavirus types is associated with age and cytologic abnormalities. Sex. Transm. Dis. 30 (7), 581–587 (2003).
15. Moscicki AB. Impact of HPV infection in adolescent populations. J. Adolesc. Health 37 (6 Suppl.), S3 –S9 (2005).
16. Collins S, Mazloomzadeh S, Winter H et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG 109 (1), 96–98 (2002).
17. Munoz N, Mendez F, Posso H et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J. Infect. Dis. 190 (12), 2077–2087 (2004).
18. Sellors JW, Karwalajtys TL, Kaczorowski J et al. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ 168 (4), 421–425 (2003).
19. Castle PE, Schiffman M, Herrero R et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J. Infect. Dis. 191 (11), 1808–1816 (2005).
20. Herrero R, Hildesheim A, Bratti C et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J. Natl Cancer Inst. 92 (6), 464–474 (2000).
21. Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int. J. Cancer 106 (6), 896–904 (2003).
22. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet. Gynecol. 92 (4 Pt 2), 727–735 (1998).
23. Schlecht NF, Platt RW, Duarte-Franco E et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J. Natl Cancer Inst. 95 (17), 1336–1343 (2003).
24. Schiffman M, Castle PE. Human papillomavirus: epidemiology and public health. Arch. Pathol. Lab. Med. 127 (8), 930–934 (2003).
25. Trottier H, Mahmud S, Lindsay L, Jenkins D, Wieting S, Franco E. Natural history of HPV infection and cervical lesions in women from the placebo arm of an AS04 adjuvanted HPV-16/18 L1 vaccine trial. EUROGIN 2006.
26. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J. Clin. Virol. 32 (Suppl. 1), S16 –S24 (2005).
27. National Cancer Institute. SEER – Cancer Statistics Review, 1973–1998. MD, USA, 2001.
28. Liu S, Semenciw R, Mao Y. Cervical cancer: the increasing incidence of adenocarcinoma and adenosquamous carcinoma in younger women. CMAJ 164 (8), 1151–1152 (2001).
29. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States – a 24-year population-based study. Gynecol. Oncol. 78 (2), 97–105 (2000).
30. Andersson S, Larson B, Hjerpe A et al. Adenocarcinoma of the uterine cervix: the presence of human papillomavirus and the method of detection. Acta Obstet. Gynecol. Scand. 82 (10), 960–965 (2003).
31. Harper DM. Why am I scared of HPV? CA Cancer J. Clin. 54 (5), 245–247 (2004).
32. Naumann RW, Crispens MA, Alvarez RD, Partridge EE, Shingleton HM, Kilgore LC. Treatment of cervical dysplasia with large loop excision of the transformation zone: is endocervical curettage necessary? South. Med. J. 89 (10), 961–965 (1996).
33. ACOG Committee on Practice Bulletins. ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists. Number 45, August 2003. Cervical cytology screening. Obstet. Gynecol. 102 (2), 417–427 (2003).
34. Saslow D, Runowicz CD, Solomon D et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J. Clin. 52 (6), 342–362 (2002).
35. Boyle P, Autier P, Bartelink H et al. European Code Against Cancer and scientific justification: third version (2003). Ann. Oncol. 14 (7), 973–1005 (2003).
36. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 287 (16), 2120–2129 (2002).
37. National Health Services. Making a difference – NHS cervical screening programme. Annual review 2004. NHS, UK, 2004.
38. Melnikow J, Birch S. Human papillomavirus triage of atypical squamous cells of undetermined significance: cost-effective, but at what cost? J. Natl Cancer Inst. 98 (2), 82–83 (2006).
39. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol. Oncol. 99 (3 Suppl. 1), S7 –S11 (2005).
40. Cuzick J, Sasieni P. Natural history of cervical human papillomavirus. Lancet 358 (9292), 1550–1551 (2001).
41. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362 (9399), 1871–1876 (2003).
42. Cuzick J, Sasieni P, Davies P et al. A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions. Br. J. Cancer 83 (5), 561–565 (2000).
43. Castle PE, Lorincz AT, Mielzynska-Lohnas I et al. Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible. J. Clin. Microbiol. 40 (3), 1088–1090 (2002).
44. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J. Natl Cancer Inst. 93 (4), 293–299 (2001).
45. van Doorn LJ, Quint W, Kleter B et al. Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J. Clin. Microbiol. 40 (3), 979–983 (2002).
46. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55 (2), 74–108 (2005).
47. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (9518), 1247–1255 (2006).
48. Viscidi RP, Kotloff KL, Clayman B, Russ K, Shapiro S, Shah KV. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin. Diagn. Lab. Immunol. 4 (2), 122–126 (1997).
49. Christensen ND, Hopfl R, DiAngelo SL et al. Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J. Gen. Virol. 75 (Pt 9), 2271–2276 (1994).
50. Hagensee ME, Olson NH, Baker TS, Galloway DA. Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids. J. Virol. 68 (7), 4503–4505 (1994).
51. Rose RC, Reichman RC, Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J. Gen. Virol. 75 (Pt 8), 2075–2079 (1994).
52. Breitburd F, Kirnbauer R, Hubbert NL et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69 (6), 3959–3963 (1995).
53. Suzich JA, Ghim SJ, Palmer-Hill FJ et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl Acad. Sci. USA 92 (25), 11553–11557 (1995).
54. Kirnbauer R, Chandrachud LM, O’Neil BW et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219 (1), 37–44 (1996).
55. Tong NK, Beran J, Kee SA et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 68 (5), 2298–2303 (2005).
56. Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24 (33–34), 5937–5949 (2006).
57. Adab P. The immunology of vaccination. In: Vaccines. 4th Edition. Plotkin SA, Orenstein WA, Offit PA (Eds). PA, USA, 31–45 (2004).
58. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2 (8), 675–680 (2001).
59. Tapping RI, Akashi S, Miyake K, Godowski PJ, Tobias PS. Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J. Immunol. 165 (10), 5780–5787 (2000).
60. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J. Immunol. 165 (2), 618–622 (2000).
61. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388 (6640), 394–397 (1997).
62. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu. Rev. Immunol. 17, 593–623 (1999).
63. Brightbill HD, Libraty DH, Krutzik SR et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 285 (5428), 732–736 (1999).
64. Kaiser P, Rothwell L, Galyov EE, Barrow PA, Burnside J, Wigley P. Differential cytokine expression in avian cells in response to invasion by Salmonella typhimurium, Salmonella enteritidis and Salmonella gallinarum. Microbiology 146 (Pt 12), 3217–3226 (2000).
65. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol. 2 (10), 947–950 (2001).
66. Baldridge JR, Yorgensen Y, Ward JR, Ulrich JT. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 18 (22), 2416–2425 (2000).
67. De Becker G, Moulin V, Pajak B et al. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int. Immunol. 12 (6), 807–815 (2000).
68. Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, Baldridge JR. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev. Vaccines 2 (2), 219–229 (2003).
69. Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm. Biotechnol. 6, 495–524 (1995).
70. Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (9447), 1757–1765 (2004).
71. Schwarz TF. An AS04-containing human papillomavirus (HPV) 16/18 vaccine for prevention of cervical cancer is immunogenic and well-tolerated in women 15–55 years old. J. Clin. Oncol. 24 (18S), 1008 (2006).
72. Dubin G. Enhanced immunogenicity of a candidate human papillomavirus (HPV) 16/18 L1 virus-like particle (VLP) vaccine with novel AS04 adjuvant in pre-teens/adolescents. ICAAC 2005.
73. Rombo L, Dubin G. AS04 adjuvanted human papillomavirus (HPV) 16/18 L1 virus-like particle (VLP) vaccine for the prevention of cervical cancer is well-tolerated and immunogenic in 10-to-14-year-old adolescent girls. ESPID 2006.
74. CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rpt 55 (RR-15), 1–48 (2006).
75. Frazer IH, Cox JT, Mayeaux EJ Jr et al. Advances in prevention of cervical cancer and other human papillomavirus-related diseases. Pediatr. Infect. Dis. J. 25 (2 Suppl.), S65 –S81 (2006).
76. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg. Infect. Dis. 10 (11), 1915–1923 (2004).
77. Ogilvie GS, Patrick DM, Schulzer M et al. Diagnostic accuracy of self collected vaginal specimens for human papillomavirus compared to clinician collected human papillomavirus specimens: a meta-analysis. Sex. Transm. Infect. 81 (3), 207–212 (2005).
78. Cuschieri KS, Cubie HA. The role of human papillomavirus testing in cervical screening. J. Clin. Virol. 32 (Suppl. 1), S34 –S42 (2005).
79. Rohan TE, Burk RD, Franco EL. Toward a reduction of the global burden of cervical cancer. Am. J. Obstet. Gynecol. 189 (4 Suppl.), S37 –S39 (2003).
80. Bosch FX. The aetiology of cervical cancer. NHSCSP 22 (2005).
81. Laimins LA. The biology of human papillomaviruses: from warts to cancer. Infect. Agents Dis. 2 (2), 74–86 (1993).
82. Genther SM, Sterling S, Duensing S, Munger K, Sattler C, Lambert PF. Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle. J. Virol. 77 (5), 2832–2842 (2003).
83. Nakagawa S, Yoshikawa H, Yasugi T et al. Ubiquitous presence of E6 and E7 transcripts in human papillomavirus-positive cervical carcinomas regardless of its type. J. Med. Virol. 62 (2), 251–258 (2000).